Chiron's Liverpool Plant Cleared to Supply Flu Vaccines After Contamination Concerns

Strategic Insights -

British regulators yesterday lifted a suspension on Chiron's Liverpool plant, allowing the company to restart manufacturing flu vaccines, following satisfactory changes and pledges to provide weekly updates. This decision is crucial in preventing a severe flu vaccine shortage in the US for the 2005-2006 season. Chiron and Sanofi-Aventis are the primary providers of flu vaccines to the US. The lift in restrictions on Chiron's plant comes as a relief to those concerned about the potential for another flu vaccine shortage, after last year's decision to block about 50m doses of Chiron's Fluvirin vaccine led to serious public health fall-out.

Key Takeaways:

  • Chiron's Liverpool plant in the UK has been cleared to supply flu vaccines after concerns over bacterial contamination were addressed.
  • The UK's Medicines and Healthcare products Regulatory Agency (MHRA) lifted the suspension on the plant, allowing manufacturing to restart after Chiron made satisfactory changes and pledged weekly updates.
  • The clearance for Chiron's Liverpool plant will help to avert another US flu vaccine shortage for the 2005-2006 season.
  • Chiron and Sanofi-Aventis are the primary providers of flu vaccines to the US, with Chiron supplying about half of the anticipated vaccine supply.
  • About 36,000 people die in the US each year from flu, according to the Center for Disease Control.
  • Estimates suggest that the flu kills about 500,000 people worldwide each year.
  • Chiron's clearance is conditional on continuous improvements at the plant, and the company expects the US Food and Drug Administration to inspect the plant.

Statistics:

  • About 50m doses of Chiron's Fluvirin vaccine were blocked last year due to contamination concerns, representing about half of the anticipated US vaccine supply.
  • The flu kills about 500,000 people worldwide each year, according to estimates.
  • About 36,000 people die in the US each year from flu, according to the Center for Disease Control.

Sources:

  • "Time was running out for Chiron to supply vaccines for next season."

+ Source: US health officials at the Center for Disease Control

  • "Chiron shares surged 10 per cent to Dollars 38.77 in early trading."

+ Source: unknown (article)

  • "Satisfactory progress has been made in manufacturing areas which had previously caused concern."

+ Source: Medicines and Healthcare products Regulatory Agency (MHRA)